Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

Por Loupakis, F, Schirripa, M, Caparello, C, Funel, N, Pollina, L, Vasile, E, Cremolini, C, Salvatore, L, Morvillo, M, Antoniotti, C, Marmorino, F, Masi, G, Falcone, A
Publicado em 2013

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

Por Schirripa, M, Bergamo, F, Cremolini, C, Casagrande, M, Lonardi, S, Aprile, G, Yang, D, Marmorino, F, Pasquini, G, Sensi, E, Lupi, C, De Maglio, G, Borrelli, N, Pizzolitto, S, Fasola, G, Bertorelle, R, Rugge, M, Fontanini, G, Zagonel, V, Loupakis, F, Falcone, A
Publicado no Br J Cancer (2015)

PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of...

Por Marmorino, F., Cremolini, C., Loupakis, F., Antoniotti, C., Barbara, C., Dargenio, F., Miraglio, E., Masi, G., Salvatore, L., Schirripa, M., Borelli, B., Marcucci, L., Antonuzzo, L., Chiara, S., Banzi, C., Amoroso, D., Bonetti, A., Martignetti, A., Paris, M., Boni, L., Tomcikova, D., Falcone, A.
Publicado no Ann Oncol (2016)